UNTERNEHMENSDATEN
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated w …
KURSVERLAUF
1T
-1,7 %
1W
+3,6 %
1M
+20,9 %
6M
+36,7 %
YTD
+12,7 %
1J
+30,5 %
2J
+44,4 %
5J
-83,8 %
10J
–
FRAG DIE AGENTEN ZU IKT
Keine Anlageberatung. Für die vollständige Analyse-Übersicht: zur Analyse-Seite →
ANALYSTEN-EINSCHÄTZUNG
KURSZIEL TIEF
5,00 $
KONSENS
5,00 $
MEDIAN
5,00 $
KURSZIEL HOCH
5,00 $
0
STRONG BUY
0
BUY
2
HOLD
0
SELL
0
STRONG SELL
2
GESAMT · Hold
| DATUM | ANALYSTENHAUS | RATING | AKTION |
|---|---|---|---|
| 28.03.2025 | HC Wainwright & Co. | Neutral | maintain |
| 12.02.2025 | HC Wainwright & Co. | Buy → Neutral | downgrade |
| 14.10.2024 | HC Wainwright & Co. | Buy | maintain |
| 16.08.2024 | HC Wainwright & Co. | Buy | maintain |
| 21.05.2024 | HC Wainwright & Co. | Buy | maintain |
| 07.03.2024 | HC Wainwright & Co. | Buy | maintain |
| 05.03.2024 | HC Wainwright & Co. | Buy | maintain |
| 15.08.2023 | HC Wainwright & Co. | Buy | maintain |
KENNZAHLEN
KGV
-4,28
KBV
1,35
EV/EBITDA
-4,74
EIGENKAPITALRENDITE
-9,8 %
NETTOMARGE
0 %
VERSCHULDUNG (D/E)
0
DIVIDENDENRENDITE
0 %
STAND
31.03.2026
FREE FLOAT & LIQUIDITÄT
STREUBESITZ
122,4 %
AKTIEN IM STREUBESITZ
161.556.897
Ø TAGESVOLUMEN (30T)
1.071.460
INVESTIERTE FONDS
| FONDS / INSTITUTION | ANTEILE | VERÄNDERUNG | STAND |
|---|---|---|---|
| GAMMA Investing LLC | 0 | -411 | 30.06.2026 |
| Sands Capital Ventures, LLC | 13.018.965 | +0 | 31.03.2026 |
| Soleus Capital Management, L.P. | 10.875.000 | +0 | 31.03.2026 |
| Fairmount Funds Management LLC | 8.625.000 | +0 | 31.03.2026 |
| ADAR1 Capital Management, LLC | 6.606.572 | -1.457.377 | 31.03.2026 |
AKTIENSPLITS
| DATUM | VERHÄLTNIS |
|---|---|
| 30.06.2023 | 1:6 |
Keine Anlageberatung. Vergangene Wertentwicklung ist kein Indikator für zukünftige Ergebnisse.